Oligomeric amyloid-beta (Aβ oligomer (or AβO))

Oligomeric amyloid-beta refers to soluble, aggregated assemblies of amyloid-beta (Aβ) peptides, typically ranging from dimers to higher-order multimers such as tetramers, hexamers, dodecamers, and up to ~20-mers[3][9]. These oligomers form spontaneously from Aβ monomers, which are proteolytic fragments derived from amyloid precursor protein (APP)[1][3]. Compared to monomeric and fibrillar Aβ, oligomeric Aβ species are believed to be the most neurotoxic, capable of disrupting synaptic signaling, impairing neuronal plasticity, and driving the early cognitive decline in Alzheimer's disease[5][6][7]. Oligomeric Aβ can interact with neuronal membranes, disrupt synaptic function, and induce inflammation and immune dysregulation by impacting antigen-presenting cells such as microglia and dendritic cells[2]. Oligomeric Aβ also demonstrates conformational diversity (e.g., type 1 out-of-register sheets and type 2 in-register sheets) as revealed by their reactivity to conformation-specific antibodies[4][11]. These molecules are a central therapeutic target in Alzheimer’s drug development, as interventions that target, neutralize, or clear Aβ oligomers are considered promising strategies to halt or reverse disease progression[5][6][9]. However, clinical targeting is complicated by their transient, heterogeneous nature, and safety concerns with immunotherapy remain significant.

Other names

amyloid-beta oligomerAβ oligomerAβOamyloid β-oligomerbeta-amyloid oligomeroligomeric Aβoligomeric amyloid-beta peptide

Antibody-mediated clearance of oligomeric and aggregated Aβ; Inhibition of Aβ oligomerization; Disruption of Aβ aggregation pathways; Neutralization of Aβ oligomers’ neurotoxic activity